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in 17,952 patients per group. Compared with control patients, AD patients had 
significantly more PPPY health care consumption in inpatient (0.70 vs. 0.28), emer-
gency room (0.67 vs. 0.31), ambulatory care (5.38 vs. 3.67), prescriptions (34.15 vs. 
23.84), Skilled Nursing Facility (SNF) (0.91 vs. 0.15), Home Health Agency (HHA) 
(0.53 vs. 0.23) and hospice (1.22 vs. 0.16). AD patients incurred significantly higher 
inpatient ($7,250 vs. $3,201), pharmacy ($4,131 vs. $2,266), SNF ($5,411 vs. $1,012), 
HHA ($1,559 vs. $641), hospice ($4,505 vs. $546) and total costs ($29,176 vs. $12,116; 
all p-values< 0.0001). ConClusions: AD is associated with a significantly higher 
economic burden compared to a control cohort.
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objeCtives: Relapsing Remitting Multiple Sclerosis (RRMS) patients treated with 
interferon beta (IFNβ ) can develop neutralizing antibodies (NAbs) that reduce 
treatment efficacy. Several clinical studies explored the association of NAb+ sta-
tus with increased disease activity. The impact of NAbs on costs has not been 
explored. The aim of this study was to estimate the cost of RRMS patients who 
develop NAbs while treated with IFNβ by the Italian National Healthcare Service 
(NHS) and the Italian Society perspectives. Methods: The study was based on a 
mixed method approach, based on both already published observational clinical 
data from an Italian study in Bari of 546 RRMS patients treated with IFNβ , and 
cost data derived from the published literature. Direct and indirect costs were 
applied stratifying patients by EDSS 0-3 and 4-6. The average rate of NAbs in IFNβ 
treated patients calculated in the Italian observational study was applied to the 
current Italian MS population treated with IFNβ . The values were inflated to Euro 
2014. Results: The direct cost per patient was estimated as € 15,428 for the NAb+ 
and € 14,317 for the NAb-. The annual societal cost per patient was estimated as 
€ 33,890 for the NAb+ and € 30,790 for the NAb-. The increase of the total annual 
costs specifically due to the NAb+ status was € 3,100 from the Italian societal 
perspective and € 1,111 from the Italian NHS perspective. Applying the average 
NAbs incidence rate, calculated in the Italian observational study (13.7%), to the 
current Italian MS population treated with IFNβ the total annual cost increases 
of approximately 3.5 million from the NHS perspective and 9.9 million from the 
societal perspective. ConClusions: The results of this economic evaluation sug-
gest the association between Nab+ status and increased costs for the management 
of RRMS. Further pharmacoeconomic research will be needed to confirm this first 
result.
PND35
The eCoNomiC buRDeN of bRaiN DisoRDeRs iN KoRea
Kim HJ, Ho SH, Lee S
Korea National Rehabilitation Center, National Rehabilitation Research Institute, Seoul, South 
Korea
objeCtives: The purpose of this study was to estimate the economic burden 
of brain disorders and provide relevant information to support health policy for 
people with brain disorders in Korea. Methods: The economic burden of brain 
disorders in Korea was estimated on the basis of direct and indirect costs using a 
prevalence-based approach. Data were retrieved from the nationwide databases 
between 2008 and 2011: Korea National Health Insurance Corporation, the National 
Disability Registry of Ministry of Health and Welfare, the Korea National Statistical 
Offices’ records of cause of death. The direct costs were those that result from pri-
mary medical and non medical expenses directly associated with brain disorders 
such as caregiver and transportation costs. The indirect costs referred to costs of 
lost opportunity due to premature death and productivity loss and a 3% discount 
rate was applied for the calculation. Results: The prevalence of brain disorders 
increased from 0.26% to 0.35% for the years 2008-2011. Total economic burden of 
brain disorders substantially increased from $1.88 billion (2008) to $2.90 billion 
(2011) by explaining approximately 54% increments of economic burden, which 
represented 0.3% of the Korean gross domestic product. According to proportion 
of costs over total economic burden, direct medical costs were increased (from 
46.4% to 59.9%) and indirect costs were decreased (from 53.6% to 40.1%) between 
2008 and 2011. By gender, male was higher burden than female approximately 
1.4~1.5 times during 2008~2011. By age groups, the cost of brain disorders was 
the highest burden aged 50 to 59 in 2011. ConClusions: The results showed 
that the prevalence and economic burden estimated from direct costs of brain 
disorders increased for the years 2008~2011. The findings supported needs of 
additional health care services and rehabilitation programs for people with brain 
disorders in Korea.
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objeCtives: In the UK, the MHRA discourages generic prescribing of certain antie-
pileptics. However, epilepsy charities advocate for greater branded prescribing, espe-
cially for antiepileptics in MHRA categories 2 and 3. We estimated: - Cost-savings 
achievable if antiepileptic prescriptions were always issued for the cheapest com-
parable drug - Additional cost if only prescribing branded antiepileptics. Methods: 
Data showing the number of antiepileptic prescriptions issued in English and Welsh 
general practices in 2014, and the associated net ingredient cost (NIC), were sourced 
from the HSCIC and NHS Wales and analysed using a proprietary in-house software. 
warranted. The study was supported by Biogen and the Swedish Research Council 
for Health, Working Life and Welfare.
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objeCtives: To assess annual health care resource utilization and direct medical 
costs for patients with epilepsy in Tianjin, China. Methods: Cross-sectional data 
were obtained from 30% random sampling Urban Employee Basic Medical Insurance 
(UEBMI) claims of Tianjin from each year of 2008 to 2013. The epileptic patients with 
≥ 1 diagnosis of epilepsy (ICD-10-CM G40/G41) before and in each calendar year were 
selected. All-cause and epilepsy-related health care resource utilization and costs of 
inpatient, outpatient and special outpatient service were assessed and comparisons 
were further conducted between “refractory” patients (treated with ≥ 3 antiepileptic 
drugs in study period) and “non-refractory” patients (treated with ≤ 2 antiepilep-
tic drugs in study period) using t-tests and chi-square tests. Results: Over 5-year 
period (from 2009 to 2013), the prevalence increased from 0.84‰ to 3.05‰. The sam-
ple patients aged 57.1 years, with 43.0% female and 15.9% of refractory in 2013. For 
epilepsy-related health services, 17.6% of patients experienced ≥ 1 hospitalizations 
in 2013, with decreased mean length of stay (2009: 48.5, 2013: 35.0), 83.8% of patients 
experienced ≥ 1 outpatient visits in 2013, while the corresponding proportions for 
special outpatient visits were 13.4% with increased mean number of visits (2009:3.6, 
2013:14.0). The epilepsy-related costs per patient decreased from 2009 ($1346) to 
2013 ($1130), among them the drug costs were the largest component (60.0%), fol-
lowed by therapeutic costs (15.4%) and examination costs (12.9 %). The all-cause 
costs stay relatively constant and were $2834 in 2013. Refractory cohort incurred 
significantly higher epilepsy-related costs than non-refractory cohort ($2237 vs $921, 
P< 0.001, 2013), which was driven by higher hospitalization rates (26% vs. 16%, P< 0.001, 
2013). ConClusions: A decreased trend of annual epilepsy-related costs over a five-
year period was associated with the less uses of inpatient services. Refractory epilepsy 
patients had as twice as much the cost of non-refractory patients.
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objeCtives: The aim of the study was to assessed the indirect costs associated 
with multiple sclerosis (MS) from the perspective of the Social Insurance Institution 
(ZUS) in Poland. Methods: The estimates were based on data from the Social 
Insurance Institution referring to year 2013 and focused on absenteeism due to 
the illness: costs of sick leave, short-term disability due to rehabilitation benefit 
and the burden of permanent (or long-term) disability due to disability pension in 
Poland. Cost analysis was performed based on the Human Capital Approach taking 
into account Gross Domestic Product (GDP) per capita (10 278 EUR) and Gross Value 
Added (GVA) per worker (24 680 EUR). Results: Total indirect costs of MS associated 
with absenteeism in the year 2013 in Poland were 73 633 786 EUR (GDP per capita) 
and 176 816 568 EUR (GVA per worker). The predominant component of absentee-
ism of MS was long-term disability (88%). Sick leave and short-term disability costs 
constituted 9% and 3% of total indirect costs of MS associated with absenteeism, 
respectively. One sick leave of person with MS generated the cost of lost productivity 
equal 451 EUR and 1 082 EUR calculated using GDP per capita and GVA per worker, 
respectively. Indirect cost of short-term disability for one entitlement to the benefit 
of rehabilitation were 4 506 EUR and 10 821 EUR, respectively. Cost of one long-term 
benefit equaled for limited period 23 866 EUR (GDP per capita) and 57 308 EUR (GVA 
per worker), and unlimited period 359 257 EUR (GDP per capita) and 862 683 EUR 
(GVA per worker) respectively. ConClusions: MS in Poland generated very high 
indirect costs. The main component was long-term disability; sick leave and reha-
bilitation benefit generated lower costs of lost productivity.
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objeCtives: Examine the economic burden and healthcare utilization of patients 
diagnosed with Alzheimer’s disease (AD). Methods: Patients diagnosed with 
AD (International Classification of Diseases, 9th Revision, Clinical Modification 
code 331.0 and ≥ 1 anti-AD prescription [donepezil, rivastigmine, galantamine, 
memantine] or a second AD diagnosis) were identified using 5% national Medicare 
data (01JAN2010–31DEC2012). The index date was the first AD diagnosis date. A 
control group was created by identifying patients without AD, AD-related dementia 
or anti-AD prescriptions using 1:1 matching based on age, gender, race, region 
and study year. The same index date and follow-up length were assigned to each 
matched pair. Patients were required to be aged 65-100 years, with continuous 
medical and pharmacy benefits for 24 months pre- and 6 months post-index date, 
and were followed until the earliest date of death, disenrollment or study end. 
One-to-one propensity score matching (PSM) were used to compare follow-up 
healthcare utilization and costs per-patient-per-year (PPPY) between the AD and 
control groups, controlling for demographics, clinical characteristics and baseline 
health-care costs. Results: A total of 96,738 patients were identified for both 
cohorts, with an average age of 83 years and 620 days follow-up. PSM resulted 
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objeCtives: This study aimed to adapt the ADPKD Outcomes Model in order to 
compare the Chronic Kidney Disease progression and relative costs of Autosomal 
Dominant Polycystic Kidney Disease (ADPKD)-affected patients treated with JINARC 
as compared to non-treated patients in Italy. Methods: Utilising the structure 
of the ADPKD Outcomes Model adapted to the Italian context, the analysis has 
simulated the evolution of ADPKD patients over a period of 80 years. The study 
was performed from both the National Health Service and social perspectives. The 
ADPKD Outcomes Model is based on a series of annual simulations at the individual 
patient level that allows clinical evolutions, such as the achievement of end-stage 
renal disease (ESRD). The model is able to incorporate country-specific pathways for 
ESRD-affected patients, such as haemodialysis (HD), peritoneal dialysis (PD), trans-
plant and conservative therapy, together with their different costs and mortality 
rates. Clinical data on treatment effect of tolvaptan were derived from TEMPO 3:4 
clinical trial. Results: The results show that tolvaptan is estimated to postpone the 
time-to-ESRD by a mean of around 3.7 years and increase life expectancy by a mean 
of 1.6 years. It is predicted that a larger number of ESRD events and deaths could 
be avoided among treated patients vs non-treated patients (e.g. 346 ESRD events 
avoided, and 68 deaths for ESRD avoided at 15 years). In addition, the cumulative cost 
per patient treated who reaches ESRD, compared to non-treated patient, generates 
overall savings in the medium to long-term (e.g. at 15 years, € 16.6 million saved for 
HD and € 2.0 million saved for PD). ConClusions: The use of JINARC in ADPKD 
patients permits not only a slowing down in the worsening of the disease, but also 
an increase in life expectancy and the achievement of a considerable decrease in 
direct and indirect health costs in the medium to long-term.
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objeCtives: To assess the cost-effectiveness of delayed-release dimethyl fuma-
rate (DMF) versus treatments for relapsing remitting multiple sclerosis (RRMS) 
from a Spanish Health System perspective. Methods: A decision analytic 
Markov model was developed to assess the cost-effectiveness of DMF versus IFN 
beta (IFNβ )-1a IM, IFNβ -1a 22 and 44 mcg SC, IFNβ -1b SC, glatiramer acetate (GA) 
SC, teriflunomide, fingolimod and natalizumab in RRMS patients. Based on the 
Expanded Disability Status Scale (EDSS), 21 health states were defined (EDSS 0-9 
RRMS, EDSS 0-9 SPMS and death). Disability disease progression rate, relapse rate, 
treatment disutility, adverse events, rates of withdrawal and disease related mor-
tality were assessed over a 30-year period. Data sources included published litera-
ture, clinical trials, Spanish price/tariff lists, and national population statistics. 
Results are presented as quality-adjusted life-years (QALY) and incremental cost 
effectiveness ratio (ICER). Univariate and probabilistic sensitivity analyses were 
performed. Results: DMF showed higher QALYs and lower costs compared to 
IFNβ -1a IM (0.122 QALYs; -2,761€ ), IFNβ -1a 44mcg SC (0.093 QALYs; -8,827€ ), IFNβ -1b 
SC (0.286 QALYs; -7,108€ ), GA SC (0.235 QALYs; -1,040€ ), teriflunomide (0.125 QALYs; 
-260€ ) and fingolimod (0.184 QALYs; -29,813€ ). In the comparison of DMF vs IFNβ -1a 
22 mcg SC, DMF provided incremental QALYs of 0.193 and an anticipated ICER of 
23,482€ . Compared to natalizumab, DMF showed incremental QALYs of -0.143 and 
incremental costs of -29.001€ , being less effective and cheaper. Sensitivity analyses 
demonstrated the robustness of the model. At a decision-maker’s willingness to 
pay of < 30.000€ , DMF was cost-effective in more than 80% of simulations versus 
IFN beta-1a IM, IFNβ -1a 44 mcg SC, IFNIβ -1b SC and GA SC; in 52% of simulations 
versus INFβ -1a 22 mcg SC; in 65% of simulations versus teriflunomide; and in 100% 
of simulations versus fingolimod. ConClusions: In this analysis DMF showed 
dominance in ICER against IFNβ -1a IM, IFNβ -1a 44 mcg SC, IFNβ -1b SC, GA SC, 
teriflunomide and fingolimod.
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objeCtives: Congenital Adrenal Hyperplasia (CAH) is one of the core conditions 
for which all states plus D.C. require newborn screening. Yoo and Grosse (2009) 
(Y/G) performed a CEA using a national incidence figure, indicating a lack of cost-
effectiveness for CAH screening (ICER, $292,000/life year gained). However, the 
incidence of the disease varies among the states, which could affect the cost-
effectiveness of the screening. Here we examine variability in that ICER due to 
variation in state incidence. Methods: We reconstructed a decision tree from Y/G 
to reproduce their deterministic ICER for CAH screening. We then ran the model 
for every state having a record of cases of CAH in the last year we were able to find 
incidence measures for most states (2006) to estimate ICERs by state. Results: 
We were able to approximately reproduce the Y/G result for the ICER ( $293,927 
per life year saved vs. $ 292,000 from Y/G, difference < 1%). After excluding states 
with missing data (5) and states with zero measured 2006 incidence (13), the ICERs 
of the remaining 33 states are shown, as expected, to inversely relate to the state 
incidence. The ICERs ranged from $37,535 (D.C.) to $1,514,018 (Illinois) per life year 
saved (median, $303,555). Three of the 33 states have ICERs less than $150,000 per 
life year. ConClusions: Different incidences of CAH have a clear effect on the 
Y/G ICERs of CAH newborn screening. In contrast to the general results from Y/G, 
using a national average incidence, 3 states have ICERs in a range that indicates 
possible cost-effectiveness in a deterministic model (ICER < $ 150,000), suggest-
ing that a PSA may be an interesting extension to assess the level of uncertainty 
around the state-level ICER estimates.
Pack-size data were sourced from the NHSBA December 2014 Drug Tariff and BNF 
68. A ‘comparable’ drug had the same active ingredient, concentration and admin-
istration method as the prescribed drug. Cost-savings, had the cheapest compa-
rable drugs been prescribed, were calculated as: [total NIC in 2014] – ([total mg of 
prescribed drugs] x [£/mg of cheapest comparable drugs]). The branded cost range, 
had only branded prescribing occurred, was calculated as: [total mg of prescribed 
drugs] x [£/mg of the most or least expensive branded comparable drugs]. Results: 
Actual total NIC for antiepileptics in 2014 was £498,552,273. Had the cheapest com-
parable drug always been prescribed, this would have decreased by £95,853,020. 
The greatest cost-savings would have been in MHRA categories 2 (40%) and 3 (44%). 
Had branded prescribing always occurred, total NIC would have increased between 
£58,988,547 (if cheapest branded drug prescribed) and £86,315,621 (if most expensive 
branded drug prescribed). The greatest increase would have been in MHRA category 
2 (£34,267,393 to £44,191,174). ConClusions: It was estimated that greater branded 
prescribing of antiepileptics would have increased total NIC by between 12% and 
17%. Only prescribing generically could have decreased total NIC by 19%. These 
estimates should be considered in light of increased risk for, and associated cost 
of, therapeutic failure.
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objeCtives: To describe relationships among persistency with subcutaneous inter-
feron beta-1a (scIFNβ 1a), relapse timing relative to discontinuation, and medical 
costs in patients with multiple sclerosis (MS). Methods: Patients (aged 18-63 years) 
with ≥ 1 MS claim (ICD-9-CM:340.xx) and an initial scIFNβ 1a claim (index event), 12 
months of continuous eligibility before and 24 months after index were identified 
in the IMS PharMetrics Plus™ database. Discontinuation was defined as a ≥ 90 day 
gap in scIFNβ 1a therapy. Relapse was defined as the first post-index MS-related 
inpatient stay, emergency room (ER) visit or MS outpatient visit with a corticosteroid 
claim ±7 days. Relapse was categorized as before or after scIFNβ 1a discontinuation. 
Medical costs [excluding disease-modifying drug (DMD) costs] per day (US$) pre or 
post discontinuation of scIFNβ 1a are presented. Costs were evaluated with general-
ized linear regression models using gap, time of first relapse and the interaction 
as predictors. Prior costs, age, gender and time until relapse were evaluated as 
covariates. Results: 1540 MS patients met the study criteria; 29.2% had a relapse 
and 50% (n= 770) discontinued scIFNβ 1a during the follow-up period. Patients dis-
continuing scIFNβ 1a averaged 250 (SD= 182) days of treatment and 33.1% relapsed, 
while those who did not discontinue averaged 726 (SD= 15) days of treatment and 
25.2% relapsed (p< 0.01). Non-DMD medical cost/day was lowest for patients with no 
gap and no relapse ($24.71/day). Patients who discontinued scIFNβ 1a and had their 
first relapse after discontinuation, had non-DMD medical costs of $39.04/day prior 
to discontinuation, and $52.29/day after discontinuation. Patients with no gap and a 
relapse while scIFNβ 1a was available had lower non-DMD medical costs ($38.88/day), 
than patients with a gap in scIFNβ 1a that experienced a relapse while on treatment 
($72.37/day). Models suggest that costs differ depending on gap status and timing 
of the relapse relative to scIFNβ 1a discontinuation (p< 0.01). ConClusions: These 
results suggest the value of maintaining scIFNβ 1a treatment.
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objeCtives: To analyze factors of recent evolution of Multiple Sclerosis 
(MS) Disease Modifying Therapies (DMT) budgets in Spain between 2004 and 
2014. Methods: 2004-2014 single DMT monthly expenditure was provided by IMS 
Health. For each DMT line: (First line: subcutaneous and intramuscular interferon 
(IFN) β -1a, subcutaneous IFN β -1b and glatiramer acetate injection. Second line: 
natalizumab and fingolimod) were calculated monthly and annually evolution of 
number of patients, billing, drug cost per patient and cost per year of treatment. 
Two periods: 2004-2014 and 2007 (start marketing second lines DMT)-2014 period 
were analyzed for each DMT line. Results: During 2004-2014 DMT expenditure 
increased from 115.5M€ to 353.8M€ due to: A greater number of patients 165% 
(10.27% annual growth per year) and a further growth of annual cost per patient: 
15.82% (1.48 % annual growth per year). In December 2014 second lines correspond 
to a 35.63% of DMT expenditure. Annual cost per patient in second line represents 
53% over cost per treated patient and 82% greater than first line DMT cost per 
year. If year 2007 is omitted from analysis (Only 68 second-line treatments and 
1.44M€ of associated expense) and is analyzed 2008-2014 period, second-line DMT 
represent 61% of new treatments causing a 78% increase in DMT expenditure. In 
2014 second line DMT participation reaches 86% of new regimens causing the 
91.23% of increase DMT expenditure. ConClusions: The growing incorporation 
of new therapies and the appreciable rise in the number of treated patients (10.27 
% annual growth per year) are components to consider in the pharmaceutical 
budget management.
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